Biblio
Export 2657 results:
Author [ Title
Filters: First Letter Of Last Name is S [Clear All Filters]
“Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load.”, J Alzheimers Dis, vol. 76, no. 1, pp. 291-301, 2020.
, “Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1053-1060, 2018.
, “Serum Copper is not Altered in Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1427-1432, 2018.
, “Serum Copper is not Altered in Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1427-1432, 2018.
, “Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.”, J Alzheimers Dis, vol. 65, no. 3, pp. 793-806, 2018.
, “Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.”, J Alzheimers Dis, vol. 65, no. 3, pp. 793-806, 2018.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Sensing of Alzheimer's Disease and Multiple Sclerosis Using Nano-Bio Interfaces.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1187-1202, 2017.
, “Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).”, J Alzheimers Dis, vol. 58, no. 4, pp. 1217-1228, 2017.
, “Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).”, J Alzheimers Dis, vol. 58, no. 4, pp. 1217-1228, 2017.
, “Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change.”, J Alzheimers Dis, vol. 71, no. 3, pp. 785-795, 2019.
, “Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change.”, J Alzheimers Dis, vol. 71, no. 3, pp. 785-795, 2019.
, “Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change.”, J Alzheimers Dis, vol. 71, no. 3, pp. 785-795, 2019.
, “Selenomethionine Attenuates the Amyloid-β Level by Both Inhibiting Amyloid-β Production and Modulating Autophagy in Neuron-2a/AβPPswe Cells.”, J Alzheimers Dis, vol. 59, no. 2, pp. 591-602, 2017.
, “Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome.”, J Alzheimers Dis, vol. 85, no. 1, pp. 153-165, 2021.
, “A Selection of Important Genes and Their Correlated Behavior in Alzheimer's Disease.”, J Alzheimers Dis, vol. 65, no. 1, pp. 193-205, 2018.
, “Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.”, J Alzheimers Dis, vol. 82, no. 3, pp. 921-937, 2021.
, “Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.”, J Alzheimers Dis, vol. 82, no. 3, pp. 921-937, 2021.
, “Secular Trends in the Incidence of Dementia in a Multi-Ethnic Community.”, J Alzheimers Dis, vol. 60, no. 3, pp. 1065-1075, 2017.
, “Secular Trends in Dementia Prevalence and Incidence Worldwide: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 2, pp. 653-680, 2018.
, “Secular Trends in Dementia Prevalence and Incidence Worldwide: A Systematic Review.”, J Alzheimers Dis, vol. 66, no. 2, pp. 653-680, 2018.
, “Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests.”, J Alzheimers Dis, vol. 56, no. 1, pp. 249-259, 2017.
, “sAβPPα is a Potent Endogenous Inhibitor of BACE1.”, J Alzheimers Dis, vol. 47, no. 3, pp. 545-55, 2015.
, “sAβPPα is a Potent Endogenous Inhibitor of BACE1.”, J Alzheimers Dis, vol. 47, no. 3, pp. 545-55, 2015.
,